Molecular pathways: Context-dependent approaches to notch targeting as cancer therapy

Clinical Cancer Research

Volumn 18, Issue 19, 2012, Pages 5188-5195

  Egloff, Ann Marie ^a   Grandis, Jennifer R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 906024; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; LIGAND; MEDI 0639; MK 0752; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; PANOBINOSTAT; PF 3084014; R 4733; UNCLASSIFIED DRUG; VALPROIC ACID;

ADVANCED CANCER; ALZHEIMER DISEASE; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; COLORECTAL CANCER; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG MECHANISM; ENZYME INHIBITION; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC CODE; GLIOBLASTOMA; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CANCER; LIGAND BINDING; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALIGNANT MESOTHELIOMA; MELANOMA; MISSENSE MUTATION; MOLECULAR MECHANICS; MUTATION RATE; NASOPHARYNX CANCER; NEUROENDOCRINE TUMOR; NONSENSE MUTATION; NOTCH GENE; NOTCH1 GENE; NOTCH2 GENE; NOTCH3 GENE; NOTCH4 GENE; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PARALOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SARCOMA; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOLID TUMOR; THYROID CANCER; TUMOR CLASSIFICATION; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER;

CODON, NONSENSE; GENE SILENCING; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; MUTATION, MISSENSE; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR, NOTCH1; RECEPTOR, NOTCH2; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84866925791     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2258     Document Type: Article

References (49)

1. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-33.
2. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009;16:633-47.
3. de Celis JF, Bray SJ. The Abruptex domain of Notch regulates negative interactions between Notch, its ligands and Fringe. Development 2000;127:1291-302.
4. Kovall RA. More complicated than it looks: assembly of Notch pathway transcription complexes. Oncogene 2008;27:5099- 109.
5. LaVoie MJ, Selkoe DJ. The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gammasecretase and release signaling fragments. J Biol Chem 2003;278: 34427-37. (Pubitemid 37553289)
6. Ascano JM, Beverly LJ, Capobianco AJ. The C-terminal PDZ-ligand of JAGGED1 is essential for cellular transformation. J Biol Chem 2003;278:8771 -9.
7. HellstromM, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007;445:776-80. (Pubitemid 46279716)
8. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649-61. (Pubitemid 121001701)
9. Weng AP, Ferrando AA, Lee W, Morris JP 4th, Silverman LB, Sanchez- Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-71. (Pubitemid 39336870)
10. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-5.
11. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 2011;11:338- 51.
12. Lobry C, OhP, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med 2011;208: 1931-5.
13. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003;3:756- 67.
14. Roy M, Pear WS, Aster JC. The multifaceted role of Notch in cancer. Curr Opin Genet Dev 2007;17:52-9. (Pubitemid 46109291)
15. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60.
16. Agrawal N, FrederickMJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154 -7.
17. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
18. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13. (Pubitemid 350134889)
19. Jiao X, Wood LD, Lindman M, Jones S, Buckhaults P, Polyak K, et al. Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. Genes Chromosomes Cancer 2012;51:480- 9.
20. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
21. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
22. Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A 2011;108: 17761- 6.
23. Zhang TH, Liu HC, Zhu LJ, Chu M, Liang YJ, Liang LZ, et al. Activation of Notch signaling in human tongue carcinoma. J Oral Pathol Med 2011;40:37- 45.
24. Lin JT, Chen MK, Yeh KT, Chang CS, Chang TH, Lin CY, et al. Association of high levels of Jagged-1 and Notch-1 expression with poor prognosis in head and neck cancer. Ann Surg Oncol 2010; 17:2976-83.
25. Duan L, Yao J, Wu X, Fan M. Growth suppression induced by Notch1 activation involves Wnt-beta-catenin down-regulation in human tongue carcinoma cells. Biol Cell 2006;98:479- 90.
26. Donnem T, Andersen S, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM. Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor -A predicts poor survival. Cancer 2010; 116:5676-85.
27. Allen TD, Rodriguez EM, Jones KD, Bishop JM. Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res 2011;71:6010-8.
28. Zheng Q, Qin H, Zhang H, Li J, Hou L, Wang H, et al. Notch signaling inhibits growth of the human lung adenocarcinoma cell line A549. Oncol Rep 2007;17:847-52.
29. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530- 7.
30. Lee CW, Simin K, Liu Q, Plescia J, Guha M, Khan A, et al. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res 2008;10:R97.
31. Chen J, Kesari S, Rooney C, Strack PR, Shen H,WuL, et al. Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer 2010;1:822-35.
32. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010;28:17-28.
33. Baldus CD, Thibaut J, Goekbuget N, Stroux A, Schlee C, Mossner M, et al. Prognostic implications ofNOTCH1 and FBXW7mutations in adult acute T-lymphoblastic leukemia. Haematologica 2009;94:1383-90.
34. Lin L, Mernaugh R, Yi F, Blum D, Carbone DP, Dang TP. Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer. Cancer Res 2010;70: 632-8.
35. The Cancer Genome Atlas [cited 2012 Mar 1]. Available from: http:// cancergenome.nih.gov/
36. Lilly halts development of semagacestat for Alzheimer's disease based on preliminary results of phase III clinical trial. 2010 [cited 2010 Aug 17]. Available from: http:// files.shareholder.com/downloads/LLY/ 1804235759-0-395879/54b1f68f-c7b8-4c04-87d1-8c609c21f6f7/ LLY-News-2010-8-17- Product.pdf.
37. Kreft A, Harrison B, Aschmies S, Atchison K, Casebier D, Cole DC, et al. Discovery of a novel series of Notch-sparing gamma-secretase inhibitors. Bioorg Med Chem Lett 2008;18:4232-6.
38. Gu H, Deng Y, Wang J, Aubry AF, Arnold ME. Development and validation of sensitive and selective LC-MS/MS methods for the determination of BMS-708163, a gamma-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:2319-26.
39. Tong G, Wang JS, Sverdlov O, Huang SP, Slemmon R, Croop R, et al. Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral gamma-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clin Ther 2012;34: 654- 67.
40. Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol 2011;29:3529- 34.
41. Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, et al. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer 2012;48:997-1003.
42. He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X, et al. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the gammasecretase inhibitor, RO4929097. Mol Oncol 2011;5:292-301.
43. Krop IE, Kosh M, Fearen I, Savoie J, Dallob A, MAtthews C, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. 2006;24:Abstract10574
44. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010;463:E6-7.
45. Truong M, Cook MR, Pinchot SN, Kunnimalaiyaan M, Chen H. Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer. Ann Surg Oncol 2011;18:1506- 11.
46. Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H. Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery 2008;144:956-61; discussion 61-2.
47. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, Haymart M, Kunnimalaiyaan M, et al. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 2007;12:942-51. (Pubitemid 47359136)
48. Pinchot SN, Jaskula-Sztul R, Ning L, Peters NR, Cook MR, Kunnimalaiyaan M, et al. Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method. Cancer 2011;117:1386-98.
49. Mohammed TA, Holen KD, Jaskula-Sztul R, Mulkerin D, Lubner SJ, Schelman WR, et al. A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist 2011;16:835 - 43.